Form 4: Syra Health Corp Director Acquires Stock Options

Andrew Dahlem, a director at Syra Health Corp, acquired 11,581 stock options on November 14, 2024, under the company's 2022 Omnibus Equity Incentive Plan.

Summary

• Andrew Dahlem, a director of Syra Health Corp, has reported the acquisition of 11,581 stock options.
• The transaction occurred on November 14, 2024.
• The stock options were granted under the company's 2022 Omnibus Equity Incentive Plan.
• The options have an exercise price of $0.3683.
• 25% of the options vested immediately upon grant, with the remaining options vesting in 12 equal monthly installments.
• The options expire on November 14, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, which is generally viewed as neutral to slightly positive as it indicates director alignment with company performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future performance.
• The vesting schedule of the options incentivizes the director to remain engaged with the company over the next year.

Risks

• The value of the stock options is dependent on the future performance of Syra Health Corp's stock price.
• There is no guarantee that the stock price will increase above the exercise price of $0.3683.

Future Outlook

The vesting schedule of the options suggests a continued engagement of the director with the company over the next year.

Industry Context

Stock option grants are a common practice for incentivizing directors and employees in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• The vesting schedule of 25% immediately and the remainder over 12 months is a fairly standard vesting schedule for stock options.
• The exercise price of $0.3683 is specific to Syra Health Corp and would need to be compared to the current market price of the stock to determine if it is a good deal for the director.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's success.

Key Dates

Keywords

stock options, insider trading, equity incentive plan, Syra Health Corp, Andrew Dahlem, director, vesting